Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-sensitive Exon 19 Insertion and Exon 20 Insertion in Patients With Advanced Non–Small-cell Lung Cancer
Journal
Clinical Lung Cancer
Journal Volume
18
Journal Issue
3
Pages
324-3320
Date Issued
2017
Author(s)
Abstract
We analyzed the responsiveness of an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) to 2 rare EGFR mutations, exon 19 insertion and exon 20 insertion (A763_Y764 insFQEA). The response rate for exon 19 insertion was 56%, and the median time to progression was 10.4 months. The response rate for exon 20 insertion (A763_Y764 insFQEA) was 73%, and the median time to progression was 5.0 months. Both showed sensitivity to EGFR TKIs. Background The clinical responsiveness to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in non–small-cell lung cancer (NSCLC) patients with exon 19 insertion and the specific exon 20 insertion (A763_Y764 insFQEA) are still not well known. Materials and Methods We analyzed cancer specimens taken from NSCLC patients for EGFR mutations using RNA reverse transcription polymerase chain reaction or direct DNA sequencing. The clinical course and responsiveness to an EGFR TKI in patients with EGFR exon 19 insertion or exon 20 insertion (A763_Y764 insFQEA) were recorded. The published data regarding these mutations were also reviewed. Results From September 1995 to May 2015, we found 4 patients with an EGFR exon 19 insertion and 6 patients with an EGFR exon 20 insertion (A763_Y764 insFQEA) at the National Taiwan University Hospital. Among patients with an exon 19 insertion, 3 received an EGFR TKI. Of the 3 patients, 1 had a partial response, 1 had stable disease, and 1 had progressive disease. Of the 6 patients with the exon 20 insertion (A763_Y764 insFQEA), 3 received an EGFR TKI. Of those 3 patients, 2 had a partial response and 1 had progressive disease. A review of the published data, together with the data from our patients, patients with an exon 19 insertion and treated with an EGFR TKI (n = 18) had a response rate of 56% and a median time to progression of 10.4 months. Patients with the exon 20 insertion (A763_Y764 insFQEA) and treated with an EGFR TKI (n = 11) had a response rate of 73% and a median time to progression of 5.0 months. Conclusions Advanced NSCLC bearing the EGFR exon 19 insertion or exon 20 insertion (A763_Y764 insFQEA) is sensitive to EGFR TKIs. ? 2016 Elsevier Inc.
SDGs
Other Subjects
afatinib; carboplatin; cisplatin; epidermal growth factor receptor; epidermal growth factor receptor kinase inhibitor; erlotinib; gefitinib; gemcitabine; pemetrexed; tesevatinib; vinorelbine tartrate; protein kinase inhibitor; adjuvant therapy; adult; advanced cancer; aged; Article; cancer adjuvant therapy; cancer combination chemotherapy; cancer patient; clinical article; DNA sequence; exon; female; gene insertion; human; human tissue; male; middle aged; non small cell lung cancer; nucleotide sequence; overall survival; post treatment survival; reverse transcription polymerase chain reaction; treatment response; cancer staging; drug resistance; exon; gene expression regulation; genetics; lung tumor; non small cell lung cancer; pathology; proto oncogene; Taiwan; Aged; Carcinoma, Non-Small-Cell Lung; Drug Resistance; Erlotinib Hydrochloride; Exons; Female; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutagenesis, Insertional; Neoplasm Staging; Protein Kinase Inhibitors; Taiwan
Publisher
Elsevier Inc.
Type
journal article